



HHV Biotech Announces the Appointment of Peter Nibbering, Ph.D., as Chief Scientific Officer

Dr. Nibbering joins HHV Biotech from the LUMC, where he was Assistant Professor at the Department of Infectious Diseases

For Immediate Release

October 14th, 2021

-
- Dr. Nibbering has more than 30 years of experience investigating the defense against infections, including biofilm-related infections
 - HHV Biotech looks forward to his contribution developing the promising lead drug candidate HHV-001
 - The company's therapeutic focus is initially on biofilm-related infectious diseases, mostly comprising of persistent bacterial infections
-

Leiden, Noord-Holland, October 14th, 2021 -- Human Health Vision ("HHV") Biotech B.V., a company developing anti-biofilm drug candidates, today announced the appointment of Peter Nibbering, Ph.D., as Chief Scientific Officer.

"Peter's 30 years of experience researching and understanding the defense against infections, including biofilm-related infections, makes him an ideal fit as HHV Biotech's CSO," said Kim Bruin, Chief Executive Officer of HHV Biotech. "He will be instrumental in the company's biofilm research, pushing forward the development of alternatives to antibiotics, focusing on novel anti-biofilm drug candidates."

Dr. Nibbering added, "Leading the early development of HHV Biotech's pipeline presents an exciting opportunity to develop strategies and agents to prevent and/or treat bacterial infections that are not treatable with current antibiotics. It is inspiring to see the company's commitment to their mission of reducing the worldwide use of antibiotics. Their unique diversity and strong strategic focus gives me confidence that we will be able to deliver transformative treatments in an area that is in dire need of innovation. I look forward to developing our promising lead drug candidate HHV-001."

Peter Nibbering holds a Ph.D. from the University of Leiden, where he investigated the origin and differentiation of mononuclear phagocytes, using quantitative immunocytochemistry. Since 1990, Dr. Nibbering has been Associate Professor at the Leiden University Medical Center (LUMC) at the Department of Infectious Diseases, where his research group investigated host defense against infections, including biofilm-related infectious diseases. He has published more than 200 peer-reviewed papers on topics spanning pathogen-host interactions, stimulation of the innate immune system to enhance its defense against infections, biofilm formation, intracellular bacteria, persisters, and design and testing of synthetic antimicrobial peptides.

About HHV Biotech

HHV Biotech is a start-up company developing a pipeline of innovative anti-biofilm compounds for infectious diseases. HHV Biotech's therapeutic focus is initially on biofilm-related infectious diseases, mostly comprising of persistent bacterial infections. For more information, please visit <https://hhvbiotech.com/>.

Media contact:

Logan Bishop-Currey
Scientific Operations Manager
bishopcurrey@hhvbiotech.com